G1 Therapeutics Inc (NASDAQ:GTHX) Director Issuedh Rudnick Sold 10,000 Shares

G1 Therapeutics Inc (NASDAQ:GTHX) Director Issuedh Rudnick Sold 10,000 Shares

G1 Therapeutics Inc (NASDAQ:GTHX) Director Seth Rudnick sold 10,000 shares of the business’s stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $41.53, for a total transaction of $415,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Seth Rudnick also recently made the following trade(s):

On Thursday, October 4th, Seth Rudnick sold 10,000 shares of G1 Therapeutics stock. The stock was sold at an average price of $49.72, for a total transaction of $497,200.00.

On Tuesday, September 4th, Seth Rudnick sold 10,000 shares of G1 Therapeutics stock. The stock was sold at an average price of $59.95, for a total transaction of $599,500.00.

Shares of GTHX traded down $1.19 during midday trading on Friday, hitting $38.23. 197,129 shares of the company traded hands, compared to its average volume of 322,252. G1 Therapeutics Inc has a one year low of $18.03 and a one year high of $69.57. The stock has a market cap of $1.42 billion, a PE ratio of -10.71 and a beta of 1.16.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, November 7th. The company reported ($0.59) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.08. Equities analysts expect that G1 Therapeutics Inc will post -2.49 earnings per share for the current year.

Several equities research analysts have commented on GTHX shares. Zacks Investment Research raised shares of G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 8th. BidaskClub downgraded shares of G1 Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 19th. Needham & Company LLC dropped their price objective on shares of G1 Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a report on Thursday, November 8th. JPMorgan Chase & Co. upped their price objective on shares of G1 Therapeutics from $58.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, August 10th. Finally, Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Sunday, November 11th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. G1 Therapeutics presently has a consensus rating of “Buy” and an average target price of $74.00.

Institutional investors and hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC increased its position in shares of G1 Therapeutics by 484.5% during the first quarter. Cubist Systematic Strategies LLC now owns 2,794 shares of the company’s stock valued at $104,000 after buying an additional 2,316 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of G1 Therapeutics by 58.4% during the first quarter. BNP Paribas Arbitrage SA now owns 2,835 shares of the company’s stock valued at $105,000 after buying an additional 1,045 shares during the period. Pacer Advisors Inc. bought a new stake in shares of G1 Therapeutics during the third quarter valued at about $111,000. Great West Life Assurance Co. Can increased its position in shares of G1 Therapeutics by 148.3% during the second quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock valued at $113,000 after buying an additional 1,560 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. increased its position in shares of G1 Therapeutics by 44.4% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,900 shares of the company’s stock valued at $144,000 after buying an additional 1,200 shares during the period. Hedge funds and other institutional investors own 64.04% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Featured Story: Roth IRA

Related posts

Leave a Comment